Results
Of 329 patients assessed for eligibility, the final analysis comprised 160 patients (40 in each group). Losartan was the only medication that showed significantly lower levels of albuminuria after 1 week (P < 0.001). For perfusion changes, there was a statistically significant decrease in the renal perfusion in patients with obstructed kidneys in comparison to before ESWL (P = 0.003). These significant changes were present in the control or antioxidant group, whilst in the losartan and verapamil groups renal perfusion was not significantly decreased.
Introduction
Since the introduction of extracorporeal shockwave lithotripsy (ESWL) in the 1980s, millions of patients have been treated worldwide and it has become one of the most commonly performed urological procedures. According to European Association of Urology guidelines on urolithiasis, ESWL or retrograde intrarenal surgery are the first-line treatments for most renal stones of <2 cm [1] . Although the safety and effectiveness of ESWL has been established in a large number of patients, it is not completely free of side-effects. In addition to the development of local haematoma, some changes in renal function have been reported [2, 3] , although these changes are usually transient in most patients without clinical sequelae [4] .
Elevated urine albumin excretion is a well-established marker of glomerular damage [5] . Damage of renal cells is also evidenced by release of some cellular enzymes in urine (enzymuria), such as N-Acetyl-b-D-glucosaminidase (NAG), b-galactosidase, b-2-microglobulin, and c-glutamyl transaminase [6] . Recently, neutrophil gelatinase-associated lipocalin (NGAL) levels in serum and urine have been considered as real-time indicators of active kidney damage [7, 8] . The mechanisms of renal parenchymal damage from shockwaves include: the direct mechanical effect of shocks on renal tissue, regional vasoconstriction, cavitation bubbles, generation of free radicals through ischaemia/reperfusion injury, and impairment of the antioxidant defence potential in the affected tissue [9] [10] [11] [12] .
It was found that the use of antioxidants, e.g. selenium with vitamins A, C and E (selenium ACE), before ESWL protected the renal tissue from these deleterious effects through their free-radical scavenging activity [12] [13] [14] . Also, it was observed that calcium channel blockers (such as nifedipine [15] or verapamil [16] ) and mannitol [17] could lessen the damaging effect of high-energy shockwaves on renal glomerular and tubular cells. Most of these studies were conducted in animal models [12, 13] or used multiple drugs in the same patient.
Recently, the angiotensin receptor blocker (losartan) was shown to be effective in inducing recovery of renal function after relief of chronic partial unilateral ureteric obstruction. The mechanism of this was attributed to prevention of ischaemia/reperfusion injury [18] .
The present study was conducted to evaluate the protective effects of antioxidants (selenium ACE), a calcium channel blocker (verapamil) and an angiotensin receptor blocker (losartan) against ESWL-induced renal injury.
Patients and Methods
After approval of the study protocol by the local ethical committee, a randomised controlled trial (RCT) was conducted between August 2012 and February 2015. Patients were evaluated before ESWL with history, routine laboratory tests (urine analysis, serum creatinine, complete blood count, and prothrombin concentration), estimation of albuminuria and non-contrast CT. Inclusion criteria were adult patients who had a single renal stone (<2 cm) that was suitable for ESWL. Exclusion criteria were patients with diabetes or hypertension, congenital renal anomalies, moderate or marked hydronephrosis, and preoperative albuminuria (>300 mg/L).
Randomisation
Eligible patients who signed the informed consent were randomised into one of four groups using sealed closed envelopes. Group 
Intervention
The following protocol was applied for all patients in all groups. ESWL was performed using the DoLi S lithotripter (Dornier MedTech, Wessling, Germany) that was equipped with the electromagnetic shockwave source (EMSE 220F-XXP). A total of 3 000 shocks were delivered at 80 shocks/ min. The patient received 1 mg/kg pethidine i.v. for analgesia. Treatment began at machine power step 1, which delivered 49 MPa focal pressure and 0.35 mJ/mm 2 . Power was gradually increased by one step for each 200 shocks up to step 4, which delivered 70 MPa and 0.7 mJ/mm 2 .
Evaluation and Follow-Up
All the patients had urinary albumin and urinary NGAL (uNGAL) estimation before ESWL, and at 2-4 h and 1 week after ESWL. The ARCHITECT urine microalbumin kit was used to estimate levels of urine albumin using ARCHITECT c4000 system. The ARCHITECT uNGAL kit was used for estimation of uNGAL using ARCHITECT i1000 system (Abbott Diagnostics, Santa Clara, CA, USA).
Dynamic contrast-enhanced MRI (DCE-MRI) was performed before ESWL, and at 2-4 h and 1 week after ESWL, to estimate renal perfusion changes. The ratio between the intensity of the kidney and that of the aorta was used to correct for the individual variations among patients. Post-ESWL obstruction was diagnosed when there was dilatation of the ureter or pelvicalyceal system on MRI after ESWL. A single radiologist (M.A.E.) interpreted all MRI images.
The stone-free rate was evaluated after 3 months with noncontrast CT.
Outcome Measures
The primary outcome was the difference in uNGAL and albuminuria levels between all groups. Secondary outcomes were the changes in renal perfusion in DCE-MRI. The operators of the ESWL session and the assessors of the urinary tests and MRI results were blinded to patients' allocation in the four groups.
Statistical Analysis
Sample size was calculated with G*Power program (http:// www.gpower.hhu.de/en.html). Using a priori test with an effect size of 0.5 for the Wilcoxon signed-rank test with an a error protection of 0.05 provided 80% power for the sample size of 35 patients in each group.
Data analysis was performed with a commercially available program (SPSS v20). Normality of the continuous data of urinary tests was tested with the Shapiro-Wilk test. One-way ANOVA was used to compare the differences in the four groups when the data were normally distributed, while the nonparametric Kruskal-Wallis test was used when the data were not normally distributed. Post hoc analysis using the Bonferroni test was done when there were significant differences between groups. Comparisons between pre-ESWL and post-ESWL MRI renal perfusion estimates were made with the paired sample t-test. A statistically significant difference was set at P < 0.05.
Results
Of 329 patients tested for eligibility for the study inclusion criteria, 175 patients agreed to participate. They were randomised between the four groups. The final analysis was performed for 40 patients in each group. The flow of patients through study is shown in the Consolidated Standards of Reporting Trials (CONSORT) chart (Fig. 1) . Patients who discontinued treatment were noncompliant to the medication given and did not discontinue due to the development of side-effects. The patients' characters (age, sex, side, body mass index, and stone length) before ESWL were comparable between all groups ( Table 1) .
Results of Laboratory Tests
There were no statistically significant differences between all groups for the uNGAL levels at 2-4 h and 1 week after ESWL (P = 0.626 and P = 0.149, respectively; Table 1 ). However, there were statistically significant differences in albuminuria mean levels at 1 week after ESWL (P < 0.001).
Post hoc analysis revealed that losartan was the only medication that showed significantly lower levels of albuminuria after 1 week (P = 0.002).
Results of MRI
Dynamic contrast-enhanced-MRI studies were completed in 135 cases. Small haematomas (0.5-1 cm) were seen 2-4 h after ESWL in 13 (9.6%) patients (three in the control group, four in the selenium ACE group, two in the losartan group and four in the verapamil group). Of these 13 haematomas, 11 were subcapsular and two were intrarenal. One patient in the selenium ACE group had macroscopic haematuria for 7 days after ESWL that resolved with conservative treatment. Three of these hematomas had disappeared at the 1-week DCE MRI.
There was temporary obstruction of the treated renal unit in 44 patients at 1 week after ESWL due to the presence of ureteric steinstrasse. Perfusion changes of the treated kidney are shown in Table 2 . For all patients there was a statistically significant decrease in renal perfusion at 1 week after ESWL compared with before ESWL (P = 0.04). On stratification of results in relation to obstruction at 1 week post-ESWL, there were statistically significant decreases in renal perfusion in patients with obstructed kidneys compared with pre-ESWL (P = 0.003). These significant changes in renal perfusion were present in patients who received placebo or selenium ACE, while there were no significant changes in patients who received losartan and verapamil.
Outcome of ESWL
Five patients required percutaneous nephrolithotomy for failure of stone disintegration. Four of 44 patients with steinstrasse required ureteroscopic extraction of the stone 
Discussion
The protection of the kidney against possible deleterious effects of ESWL has been the goal in many previous studies [12] [13] [14] [15] [16] [17] . The evidence supporting routine use of one of the tried medications was weak because of limitations in the study design or testing drug efficacy in animal models. In the present study, we conducted a RCT to test the protective effect of three medications. One of them (losartan) was tested for the first time for the protection of the kidney against ESWL-induced renal injury after it was reported to protect the kidney from ischaemia/reperfusion injury [18] .
The efficacy of each treatment was tested by its ability to prevent a significant rise of albuminuria and uNGAL. Albuminuria indicates leakage from the injured renal glomeruli, while uNGAL indicates injury of the renal tubules. The kidney tubules produce NGAL in response to various injuries and its levels clearly correlate with severity of renal impairment [8] . Moreover, we studied renal perfusion changes at different time intervals using DCE-MRI, which is helpful in understanding the mechanism of renal damage after ESWL [19] and hence how a specific medication protected the kidney.
The first observation from the present study was that uNGAL levels after ESWL were comparable in all groups, which means that renal tubules were not significantly affected by ESWL. This may be explained by the use of the shockwaves source (EMSE 220F-XXP), which is characterised by a wider focal diameter of 3.5 mm and lower energy level (0.7 mJ/ mm 2 at power level 4). This wide-focus-low-pressure character may be the reason for decreased renal tubular injury; as detected by uNGAL. Recently, a study by Kardakos et al. [20] showed that ESWL did not cause significant rises in uNGAL levels.
The second important result was that losartan was the only treatment with significantly lower levels of albuminuria at 1-week post-ESWL. This indicates that the renal protective effects of antioxidants (selenium ACE) in animal studies [12, 13] were not confirmed in the present clinical study in humans. On the contrary, Kehinde et al. [14] reported that urinary albumen levels were significantly reduced when oral antioxidants were given. Further studies with more patients are still needed to solve this controversy.
The third observation was that renal perfusion measured by DCE-MRI was not altered at 2-4 h post-ESWL, but a significant decrease in renal perfusion was detected after 1 week in patients who developed post-ESWL renal obstruction. This means that ESWL itself has no direct effect on renal perfusion of the treated kidney. Previous studies showed that post-ESWL obstruction was the main cause of a decrease in renal perfusion and function [19, 21] .
The last relevant result was that renal perfusion in patients with obstructed kidneys was not altered in both the verapamil and losartan groups. This is very important in the protection of the kidney against post-ESWL obstruction-related renal damage caused by ischaemia/reperfusion injury. The use of losartan and verapamil in the present study was not associated with increased incidence or severity of haematomas after ESWL. This may be due to the use of a low-pressure ESWL source or healthy intrarenal vascularity of our present patients because we excluded those with hypertension or diabetes. Moreover, the stepwise power ramping protocol that was used for all patients in the present study has been shown to be associated with significantly fewer haematomas after ESWL [22] .
Limitations of the present study include the relatively few patients in each group. We calculated the sample size according to a power of 80% and an effect size of 0.5. A future study with higher power (90%) or with lower effect size (0.25) is required to confirm the results of the present study. Another limitation was testing the efficacy of the tested medications after one session of ESWL. In clinical practice, using an electromagnetic lithotripter, many patients require multiple treatment sessions. Therefore, the efficacy of losartan that was shown after one session needs to be tested again after multiple sessions of ESWL.
In conclusion, losartan was shown to protect the kidney against ESWL-induced renal injuries by significantly decreasing post-ESWL albuminuria. Verapamil and losartan maintained renal perfusion in patients with post-ESWL renal obstruction.
